Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: john.d who wrote (8023)	11/15/2001 1:46:21 AM
From: Cal Gary	Respond to of 14101

Somewhat related, Rheumatoid Arthritis, for anyone other in cyberland that may need this info: Amgen arthritis drug OK'd November 14, 2001: 2:11 p.m. ET FDA approves Kineret, Amgen's new treatment for rheumatoid arthritis. Amgen NEW YORK (CNN/Money) - The U.S. Food and Drug Administration, as expected, has approved Amgen Inc.'s new treatment for rheumatoid arthritis, which could help up to 300,000 patients. Amgen said Wednesday the FDA approved Kineret "for the reduction in signs and symptoms of moderately to severely active rheumatoid arthritis in adult patients who have failed one or more disease modifying antirheumatic drugs." Kineret has a novel mechanism that selectively and directly blocks a certain protein associated with inflammation and arthritis. An FDA advisory panel voted in favor of approval in August, and the FDA usually follows the advice of the pane. "Kineret worked for many of my patients," said Dr. Stanley Cohen, a clinical investigator for the drug's trails, in an Amgen statement. "I am impressed with the improvements in my patients' painful and swollen joints."

To: john.d who wrote (8023)	11/15/2001 1:59:18 AM
From: Joe Krupa	Read Replies (1) \| Respond to of 14101

John, "Since it is so obvious to everyone that Acqua is arbitraging/shorting the stock, you have wonder how Rebecca could say at the AGM that it wasn't happening (though she did qualify it by saying that the TSE has not identified that Acqua is breaking any rules. I assume that what they are doing is all very legal). Really calls into question the credibility of some of Rebecca's other answers that we can only trust her on (e.g comments about dialogue with the FDA that indicates that approval is expected by the end of the fiscal year)." I hear what you are saying about "the credibility of some of Rebecca's other answers" in light of her comments on Acqua, however I somewhat disagree based on the unique circumstance Dimethaid is in. DMX needs the money from Acqua right now to bridge a dry period - it's not pleasant or painless for the shareholders, but it is getting us there. We are drawing outside the original parameters of the agreement and it could likely derail the deal if Rebecca was to accuse Acqua, in a public forum, of not playing by the rules. If I were Rebecca, I think I would have given a similar answer to the question at the AGM. She was likely not being deceptive when saying it's up to the TSE to monitor the deal. If she has chosen to investigate Acqua's modus operandi beyond relying on the TSE, I suspect she is doing it in private and not publicly confronting them. So I don't believe that here comments on the Acqua issue call into question her integrity on the other things she said at the AGM. I think she said what she had to on the issue. joe